Physician profile
Andrew MD Plummer
NPI 1467982710
$4,012.02
in general payments reported to CMS, 2019-2025
18 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $51.63 · 2021: $627 · 2022: $805 · 2023: $1,028 · 2024: $756 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,189.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $883.67 | 2019-2025 | Clareon, Centurion, Hydrus Microstent |
| Abbvie INC. | $720.27 | 2022-2025 | |
| Biotissue Holdings INC. | $622.67 | 2021-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $554.84 | 2021-2025 | Tecnis Iol, Tecnis Simplicity |
| Rxsight INC | $391.43 | 2021-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Sun Pharmaceutical Industries INC. | $260.46 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $79.14 | 2019 | |
| Sight Sciences, INC. | $73.60 | 2021-2025 | Omni Surgical System |
| Allergan, INC. | $55.86 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $54.23 | 2023-2024 | Xiidra, Vyzulta, Miebo |
| Horizon Therapeutics Plc | $50.22 | 2021-2022 | |
| Ocular Therapeutix, INC. | $49.37 | 2023 | Dextenza |
| Tearlab Corp | $48.33 | 2023-2024 | Scoutpro Osmolarity System, Tearlab Osmolarity System |
| Novartis Pharmaceuticals Corporation | $46.92 | 2021-2022 | |
| Thea Pharma INC. | $39.27 | 2024-2025 | Iyuzeh |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $38.72 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $22.13 | 2023 | Tyrvaya |
| Astellas Pharma US INC | $20.89 | 2023 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Plummer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.